T6746C and P72R Polymorphisms Are Associated with the Susceptibility to Diffuse Cutaneous Systemic Sclerosis

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Mar 19

PMID 32185220

Citations 5

Authors

Szymon Zmorzynski

Magdalena Wojcierowska-Litwin

Malgorzata Kowal

Malgorzata Michalska-Jakubus

Wojciech Styk

Agata Anna Filip

Irena Walecka

Dorota Krasowska

Affiliations

Soon will be listed here.

Abstract

Results: The genotypic frequencies of the and =0.03; = 4.63). There was no significant difference between SSc patients and the control population in allele frequencies of both SNPs. The CT + CC genotypes of and =0.03; =0.03; =0.03; genes and serum anti-TP53 antibodies with the susceptibility, clinical subset of systemic sclerosis (SSc), and clinical profile of SSc patient, particularly with lung involvement and disease activity. =0.03.

Conclusion: The CT + CC genotypes of gene and PR + RR genotypes of the gene increased the risk of dcSSc development. Moreover, genotypes of CT + CC were associated with the active form of SSc suggesting the role of the NOTCH pathway in the pathogenesis of this disease. and genes and serum anti-TP53 antibodies with the susceptibility, clinical subset of systemic sclerosis (SSc), and clinical profile of SSc patient, particularly with lung involvement and disease activity.

Citing Articles

Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.

Giriyappagoudar M, Vastrad B, Horakeri R, Vastrad C Biomedicines. 2023; 11(12).

PMID: 38137330 PMC: 10740779. DOI: 10.3390/biomedicines11123109.

Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis.

Grasshoff H, Fourlakis K, Comduhr S, Riemekasten G Biomedicines. 2022; 10(9).

PMID: 36140251 PMC: 9496142. DOI: 10.3390/biomedicines10092150.

Identification of molecular mechanism and key biomarkers in membranous nephropathy by bioinformatics analysis.

Dong Z, Geng Y, Zhang P, Tang J, Cao Z, Zheng H Am J Transl Res. 2022; 14(8):5833-5847.

PMID: 36105034 PMC: 9452341.

The Genetic Variants of NOTCH3 (6746T>C) and PSMA6 (-8C>G) as Possible Risk Factors of Psoriasis Development.

Bartosinska J, Zmorzynski S, Sarecka-Hujar B, Raczkiewicz D, Wojcierowska-Litwin M, Korszen-Pilecka I Life (Basel). 2021; 11(9).

PMID: 34575036 PMC: 8467108. DOI: 10.3390/life11090887.

Notch-ing up knowledge on molecular mechanisms of skin fibrosis: focus on the multifaceted Notch signalling pathway.

Condorelli A, El Hachem M, Zambruno G, Nystrom A, Candi E, Castiglia D J Biomed Sci. 2021; 28(1):36.

PMID: 33966637 PMC: 8106838. DOI: 10.1186/s12929-021-00732-8.

References

Chung L, Lin J, Furst D, Fiorentino D . Systemic and localized scleroderma. Clin Dermatol. 2006; 24(5):374-92. DOI: 10.1016/j.clindermatol.2006.07.004. View

Dumont P, Leu J, Della Pietra 3rd A, George D, Murphy M . The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003; 33(3):357-65. DOI: 10.1038/ng1093. View

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View

Herkel J, Kam N, Erez N, Mimran A, Heifetz A, Eisenstein M . Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA. Eur J Immunol. 2004; 34(12):3623-32. DOI: 10.1002/eji.200425371. View

Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman A, DAngelo S . European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001; 60(6):592-8. PMC: 1753669. DOI: 10.1136/ard.60.6.592. View

Yang Q, Khoury M, Friedman J, Little J, Flanders W . How many genes underlie the occurrence of common complex diseases in the population?. Int J Epidemiol. 2005; 34(5):1129-37. DOI: 10.1093/ije/dyi130. View

Choi A, Nam S, Kim W, Park S, Kim H, Yang C . Notch signaling in the collecting duct regulates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction in mice. Korean J Intern Med. 2017; 33(4):774-782. PMC: 6030409. DOI: 10.3904/kjim.2016.230. View

Mimura Y, Yazawa N, Tada Y, Ihn H, Tamaki K . Anti-p53 antibodies in patients with systemic sclerosis. Int J Dermatol. 2007; 46(5):549-50. DOI: 10.1111/j.1365-4632.2007.03239.x. View

Dees C, Tomcik M, Zerr P, Akhmetshina A, Horn A, Palumbo K . Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis. 2011; 70(7):1304-10. DOI: 10.1136/ard.2010.134742. View

10.

Gabrielli A, Avvedimento E, Krieg T . Scleroderma. N Engl J Med. 2009; 360(19):1989-2003. DOI: 10.1056/NEJMra0806188. View

11.

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

12.

Noseda M, McLean G, Niessen K, Chang L, Pollet I, Montpetit R . Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ Res. 2004; 94(7):910-7. DOI: 10.1161/01.RES.0000124300.76171.C9. View

13.

van den Hoogen F, Khanna D, Fransen J, Johnson S, Baron M, Tyndall A . 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013; 72(11):1747-55. DOI: 10.1136/annrheumdis-2013-204424. View

14.

Mahmoudi M, Abed Khojasteh M, Alsahebfosoul F, Gharibdoost F, Mostafaei S, Ganjalikhani-Hakemi M . Expressions of p53 and PUMA in fibroblasts of systemic sclerosis patients are normal at transcription level. J Cosmet Dermatol. 2017; 17(3):549-554. DOI: 10.1111/jocd.12420. View

15.

Kruiswijk F, Labuschagne C, Vousden K . p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol. 2015; 16(7):393-405. DOI: 10.1038/nrm4007. View

16.

Awad El-Sayed Z, Farag D, Eissa S . Tumor suppressor protein p53 and anti-p53 autoantibodies in pediatric rheumatological diseases. Pediatr Allergy Immunol. 2003; 14(3):229-33. DOI: 10.1034/j.1399-3038.2003.00033.x. View

17.

Lassaletta A, Elmadhun N, Burgess T, Bianchi C, Sabe A, Robich M . Microvascular notch signaling is upregulated in response to vascular endothelial growth factor and chronic myocardial ischemia. Circ J. 2013; 78(3):743-51. DOI: 10.1253/circj.cj-13-0685. View

18.

Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S . Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol. 2009; 50(5):969-79. DOI: 10.1016/j.jhep.2008.12.032. View

19.

Lafyatis R . Transforming growth factor β--at the centre of systemic sclerosis. Nat Rev Rheumatol. 2014; 10(12):706-19. DOI: 10.1038/nrrheum.2014.137. View

20.

Chen Y, Zheng S, Qi D, Zheng S, Guo J, Zhang S . Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One. 2012; 7(10):e46512. PMC: 3463607. DOI: 10.1371/journal.pone.0046512. View